Outcomes
ADVERSE EFFECTS, SECONDARY
The primary outcome of this study was to evaluate the efficacy of CPT-FPV in preventing hospitalization within 14 and 28 days while demonstrating its non-inferiority to sotrovimab in treating mild-to-moderate COVID-19 cases in outpatient settings. The secondary outcomes included assessing the rates of oxygen supplementation, emergency department visits within 14 and 28 days, utilization of invasive mechanical ventilation, ICU admission, mortality, clinical improvement, non-clinical progression, and changes in inflammatory biomarkers on days 2, 5, and 14. Additionally, virologic, radiologic, and cytokine measurements were taken on days 0, 5, and 14, and any observed adverse effects were recorded.